Prevention of mother-child transmission programs work but infants need checking for drug resistance

March 29, 2011

Genetic mutations that lead to antiretroviral (the drugs used to treat HIV/AIDS) resistance in HIV-infected infants may develop as a result of exposure to low doses of maternal antiretroviral drugs via breastfeeding rather than being acquired directly from the mother. This key finding from a study by Clement Zeh from the US Centers for Disease Control and Prevention, Kisumu, Kenya, and colleagues, published in this week's PLoS Medicine, is important as it may impact the choice of drug regimen given to HIV-infected breastfeeding mothers and their infected infants—an effective intervention which has been shown to substantially reduce the overall rate of mother-to-child transmission of the HIV virus.

The authors conducted a secondary analysis (or substudy) of The Kisumu Breastfeeding Study—a trial in Kisumu, Kenya by Timothy Thomas and colleagues from the Kenya Medical Research Institute (KEMRI) and CDC, Kisumu, Kenya, and colleagues also reported in this week's . The Kisumu Breastfeeding Study assessed the safety and transmission rates of a triple-antiretroviral regimen (zidovudine, lamivudine, and either nevirapine or nelfinavir) given to HIV-infected women a few weeks before giving birth (34 wk gestation) through 6 months of breastfeeding. The study documented transmission rates of 7% at 24 months, most of them due to transmission in-utero or during delivery, which is considerably lower than the 25% - 48% transmission rates reported in the absence of antiretrovirals. The authors concluded that this combination of drugs was safe and feasible in resource-limited settings.

In their secondary analysis, Clement Zeh and colleagues investigated the possible causes of the emergence of maternal ARV-associated resistance among the 24 infants who were infected with either at delivery or during 6 months of breastfeeding and thus exposed to maternal ARVs.

The authors took regular blood samples from these infants and from their mothers to look for the presence of HIV mutations. The authors found that various mutations were present in samples taken from all the HIV-positive infants whose mothers who had received nelfinavir but in only half of those taken from infants whose mothers who had received nevirapine. However exposure to nevirapine resulted in a wider range of ARV resistant mutations. In contrast, most of the mothers of HIV-positive infants had no HIV drug resistance mutations, and only one mother-infant pair had an overlapping pattern of HIV drug resistance mutations. This pattern of mutations suggests that drug resistance most likely arose through exposure of the infants to low levels of ARVs in breast milk rather than through mother-to-child transmission of drug-resistant HIV virus.

These findings need further confirmation through future studies but suggest that infants exposed to antiretroviral drugs through breast milk—a situation that may become increasingly common given the encouraging results of The Kisumu Breastfeeding Study and similar trials that show a reduction in mother-to-child-transmission—should be carefully monitored for HIV infection. Providers should consider the mother's regimen when choosing treatment for infants who are found to be HIV infected while breastfeeding and closely monitor response to therapy.

Clement Zeh and colleagues say: "The low mother-to-child HIV transmission rates observed in the trial support the role of triple-combination maternal antiretroviral therapy as a successful [Prevention of Mother-to-Child Transmission] intervention among breastfeeding HIV-infected mothers. However, the data from this secondary analysis suggest that ingestion of through breast milk may have contributed to the emergence of HIV drug resistance mutations in the infants, as we observed an increasing frequency of infants with HIV drug resistance mutations over the first 6 months of life when maternal antiretroviral therapy was given during breastfeeding."

They add: "[Prevention of Mother-to-Child Transmission] programs providing maternal antiretroviral therapy during breastfeeding and those caring for infants exposed to antiretroviral through breast milk will need to be cognizant of this issue and consider monitoring these infants more closely and tailoring their treatment accordingly."

More information: Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, et al. (2011) HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis. PLoS Med 8(3): e1000430. doi:10.1371/journal.pmed.1000430

Related Stories

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

pozlove
not rated yet Mar 30, 2011
I just saw on the news that according to a report from CDC, the number of gay people on the largest STD dating site Positive-singles. org has reached 310,000. This site is powered by plenty of fish and most of the gay people on it are sexy and good looking.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.